FindTrial
Sign In

ABBV-181

DRUG10 trials

Sponsors

AbbVie

Conditions

Advanced Solid TumorsAdvanced Solid Tumors CancerCancerColorectal CancerHIV InfectionHIV-1Head and Neck CancerHuman Immunodeficiency Virus (HIV)

Phase 1

A Study of ABT-165 in Subjects With Solid Tumors
CompletedNCT01946074
AbbVieAdvanced Solid Tumors
Start: 2013-08-08End: 2022-09-28Updated: 2023-12-15
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
Active, not recruitingNCT02988960
AbbVieAdvanced Solid Tumors Cancer
Start: 2017-02-22End: 2026-09-30Updated: 2026-01-09
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
CompletedNCT03000257
AbbVieAdvanced Solid Tumors
Start: 2016-12-14End: 2022-03-29Updated: 2022-04-14
A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
TerminatedNCT03035279
AbbVieColorectal Cancer
Start: 2017-03-08End: 2019-03-28Updated: 2020-02-20
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
CompletedNCT03071757
AbbVieAdvanced Solid Tumors Cancer
Start: 2017-03-21End: 2022-04-13Updated: 2022-04-28
SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers
TerminatedNCT03138408
AbbVieCancer
Start: 2017-06-14End: 2019-05-02Updated: 2019-05-14
A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma
TerminatedNCT03818542
AbbVieHead and Neck Cancer
Start: 2020-01-22End: 2020-09-23Updated: 2020-12-31
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Active, not recruitingNCT03893955
AbbVieAdvanced Solid Tumors, Cancer, Metastatic Solid Tumors +2
Start: 2019-05-21End: 2026-03-31Target: 150Updated: 2025-08-12
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
CompletedNCT04196283
AbbVieAdvanced Solid Tumors Cancer
Start: 2020-01-22End: 2022-10-27Updated: 2023-02-27
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1
CompletedNCT04223804
AbbVieHIV-1, HIV Infection, Human Immunodeficiency Virus (HIV)
Start: 2020-01-30End: 2023-02-27Updated: 2023-03-09

Related Papers

Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study.
2025-10-15
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.
2022-07-1648 citations
Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab
Journal of Immunotherapy2022-01-1416 citations
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
Molecular Cancer Therapeutics2021-07-2613 citations
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
2021-07-0312 citations
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer
Cancer Treatment and Research Communications2021-01-0110 citations
Abstract CT124: First-in-human study of SC-004, an antibody-drug conjugate targeting CLDN6/9, in patients with epithelial ovarian cancers
Cancer Research2020-08-153 citations
Abstract CT167: First-in-human clinical trial of SC-006, a RNF43 targeted antibody-drug conjugate, as a monotherapy and in combination with budigalimab in patients with advanced colorectal cancer
Cancer Research2020-08-151 citations
Abstract 4464: Pharmacodynamic and predictive biomarkers of clinical responses to PD-1 inhibitor budigalimab from the first-in-human clinical trial
Cancer Research2020-08-15
A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors.
Journal of Clinical Oncology2020-05-206 citations
Abstract 3950: Rovalpituzumab tesirine enhances the anti-tumor efficacy of PD-1 blockade in a murine model of small cell lung cancer with endogenous Dll3 expression
Cancer Research2019-07-011 citations
Abstract 3950: Rovalpituzumab tesirine enhances the anti-tumor efficacy of PD-1 blockade in a murine model of small cell lung cancer with endogenous Dll3 expression
Immunology2019-07-01
Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891
Annals of Oncology2018-10-014 citations
Safety, tolerability, and pharmacokinetics of the OX40 agonist ABBV-368 in patients with advanced solid tumors
Annals of Oncology2018-10-013 citations
Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC)
Annals of Oncology2018-06-015 citations
Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors.
Journal of Clinical Oncology2016-05-204 citations